Feng Li1,2, Janice M Yoshizawa2, Kyoung-Mee Kim3, Julie Kanjanapangka2, Tristan R Grogan4, Xiaoyan Wang4, David E Elashoff4, Shigeo Ishikawa2, David Chia5, Wei Liao2, David Akin2, Xinmin Yan2, Min-Sun Lee6, Rayun Choi6, Su-Mi Kim6, So-Young Kang3, Jae-Moon Bae6, Tae-Sung Sohn6, Jun-Ho Lee6, Min-Gew Choi6, Byung-Hoon Min7, Jun-Haeng Lee7, Jae J Kim7, Yong Kim8, Sung Kim9, David T W Wong8. 1. Institute of Diagnostic in Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China. 2. School of Dentistry, University of California, Los Angeles, CA. 3. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 4. Department of Medicine Statistics Core, David Geffen School of Medicine, University of California, Los Angeles, CA. 5. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA. 6. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 7. Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 8. School of Dentistry, University of California, Los Angeles, CA; dtww@ucla.edu thadyk@ucla.edu sungkimm@skku.edu. 9. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; dtww@ucla.edu thadyk@ucla.edu sungkimm@skku.edu.
Abstract
BACKGROUND: Biomarkers are needed for noninvasive early detection of gastric cancer (GC). We investigated salivary extracellular RNA (exRNA) biomarkers as potential clinical evaluation tools for GC. METHODS: Unstimulated whole saliva samples were prospectively collected from 294 individuals (163 GC and 131 non-GC patients) who underwent endoscopic evaluation at the Samsung Medical Center in Korea. Salivary transcriptomes of 63 GC and 31 non-GC patients were profiled, and mRNA biomarker candidates were verified with reverse transcription quantitative real-time PCR (RT-qPCR). In parallel, microRNA (miRNA) biomarkers were profiled and verified with saliva samples from 10 GC and 10 non-GC patients. Candidate biomarkers were validated with RT-qPCR in an independent cohort of 100/100 saliva samples from GC and non-GC patients. Validated individual markers were configured into a best performance panel. RESULTS: We identified 30 mRNA and 15 miRNA candidates whose expression pattern associated with the presence of GC. Among them, 12 mRNA and 6 miRNA candidates were verified with the discovery cohort by RT-qPCR and further validated with the independent cohort (n = 200). The configured biomarker panel consisted of 3 mRNAs (SPINK7, PPL, and SEMA4B) and 2 miRNAs (MIR140-5p and MIR301a), which were all significantly down-regulated in the GC group, and yielded an area under the ROC curve (AUC) of 0.81 (95% CI, 0.72-0.89). When combined with demographic factors, the AUC of the biomarker panel reached 0.87 (95% CI, 0.80-0.93). CONCLUSIONS: We have discovered and validated a panel of salivary exRNA biomarkers with credible clinical performance for the detection of GC. Our study demonstrates the potential utility of salivary exRNA biomarkers in screening and risk assessment for GC.
BACKGROUND: Biomarkers are needed for noninvasive early detection of gastric cancer (GC). We investigated salivary extracellular RNA (exRNA) biomarkers as potential clinical evaluation tools for GC. METHODS: Unstimulated whole saliva samples were prospectively collected from 294 individuals (163 GC and 131 non-GC patients) who underwent endoscopic evaluation at the Samsung Medical Center in Korea. Salivary transcriptomes of 63 GC and 31 non-GC patients were profiled, and mRNA biomarker candidates were verified with reverse transcription quantitative real-time PCR (RT-qPCR). In parallel, microRNA (miRNA) biomarkers were profiled and verified with saliva samples from 10 GC and 10 non-GC patients. Candidate biomarkers were validated with RT-qPCR in an independent cohort of 100/100 saliva samples from GC and non-GC patients. Validated individual markers were configured into a best performance panel. RESULTS: We identified 30 mRNA and 15 miRNA candidates whose expression pattern associated with the presence of GC. Among them, 12 mRNA and 6 miRNA candidates were verified with the discovery cohort by RT-qPCR and further validated with the independent cohort (n = 200). The configured biomarker panel consisted of 3 mRNAs (SPINK7, PPL, and SEMA4B) and 2 miRNAs (MIR140-5p and MIR301a), which were all significantly down-regulated in the GC group, and yielded an area under the ROC curve (AUC) of 0.81 (95% CI, 0.72-0.89). When combined with demographic factors, the AUC of the biomarker panel reached 0.87 (95% CI, 0.80-0.93). CONCLUSIONS: We have discovered and validated a panel of salivary exRNA biomarkers with credible clinical performance for the detection of GC. Our study demonstrates the potential utility of salivary exRNA biomarkers in screening and risk assessment for GC.
Authors: Andrew J Rosato; Xiaochun Chen; Yoshiaki Tanaka; Lindsay A Farrer; Henry R Kranzler; Yaira Z Nunez; David C Henderson; Joel Gelernter; Huiping Zhang Journal: Epigenomics Date: 2019-05-29 Impact factor: 4.778
Authors: Óscar Rapado-González; Cristina Martínez-Reglero; Ángel Salgado-Barreira; Bahi Takkouche; Rafael López-López; María Mercedes Suárez-Cunqueiro; Laura Muinelo-Romay Journal: Ann Med Date: 2020-04-11 Impact factor: 4.709
Authors: Saumya Das; K Mark Ansel; Markus Bitzer; Xandra O Breakefield; Alain Charest; David J Galas; Mark B Gerstein; Mihir Gupta; Aleksandar Milosavljevic; Michael T McManus; Tushar Patel; Robert L Raffai; Joel Rozowsky; Matthew E Roth; Julie A Saugstad; Kendall Van Keuren-Jensen; Alissa M Weaver; Louise C Laurent Journal: Cell Date: 2019-04-04 Impact factor: 66.850
Authors: Giacomo Setti; Margherita E Pezzi; Maria Vittoria Viani; Thelma A Pertinhez; Diana Cassi; Cristina Magnoni; Pierantonio Bellini; Antonino Musolino; Paolo Vescovi; Marco Meleti Journal: Int J Mol Sci Date: 2020-01-30 Impact factor: 5.923